STAAR Surgical Co (STAA) FinancialsSTAASTAAR Surgical Co

STAAR Surgical Company (STAA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ICLs, accounting for 97.4% of total sales, equivalent to $41.50M. Another important revenue stream is Other surgical products. Understanding this composition is critical for investors evaluating how STAA navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, STAAR Surgical Company maintains a gross margin of 74.55%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.80%, while the net margin is 8.61%. These profitability ratios, combined with a Return on Equity (ROE) of 1.09%, provide a clear picture of how effectively STAA converts its operational activities into shareholder value.

In the context of the broader market, STAA competes directly with industry leaders such as BVS and IRMD. With a market capitalization of $1.09B, it holds a significant position in the sector. When comparing efficiency, STAA's gross margin of 74.55% stands against BVS's 68.29% and IRMD's 74.07%. Such benchmarking helps identify whether STAAR Surgical Company is trading at a premium or discount relative to its financial performance.

STAAR Surgical has shown fluctuating financial performance, with a gross margin of 74.55% in Q2 2026 and a recent EPS of 0.16, indicating potential profitability. However, the company has faced net losses in several quarters, which raises concerns about its financial stability.